Could a single cell infusion before transplant reduce rejection?
NCT ID NCT03726307
First seen May 07, 2026 · Last updated May 20, 2026 · Updated 2 times
Summary
This early-phase study tests whether a single infusion of special immune cells (regulatory dendritic cells) from the donor, given one week before a kidney transplant, is safe and feasible. It involves 14 kidney recipients and their living donors, with recipients followed for two years. The goal is to see if this approach can lower the risk of organ rejection without increasing side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Pittsburgh, Starzl Transplantation Institute
Pittsburgh, Pennsylvania, 15213, United States
Conditions
Explore the condition pages connected to this study.